Findings
There are significant risks associated with connected sensor technologies that exceed current evaluation capabilities, including validation, security practices, data rights and governance, utility and usability, and economic feasibility.
Existing evaluation frameworks are inadequate for the unique challenges posed by digital health technologies.
The regulatory environment for digital specimens is not well-established, leading to ambiguity in oversight.

Recommendations
Develop a systematic and standardized evaluation framework for connected sensor technologies.
Implement a connected sensor technology label to improve transparency and decision-making.
Encourage innovation and modern regulatory oversight through updated guidelines.
Address the evolving distinction between regulated and unregulated digital health technologies.
Enhance communication infrastructure to make information more accessible to stakeholders.

Regulatory Considerations
The regulatory environment for digital health technologies is evolving, with a need for modern oversight.
There is ambiguity in the regulation of digital specimens, requiring clearer guidelines.
The FDA has issued guidances to encourage innovation and efficient oversight.